Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03741101
Other study ID # BUS2018-1
Secondary ID 2018-001846-32
Status Active, not recruiting
Phase Phase 2
First received
Last updated
Start date June 10, 2019
Est. completion date December 15, 2024

Study information

Verified date April 2024
Source Region Skane
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial, Treatment of NF1-related plexiform neurofibroma with trametinib; a single arm,open-label study with the goals of volumetric partial remission and pain relief (EudraCT 2018-001846-32, Sponsor protocol number BUS2018-1, related Novartis reference number CTMT212ASE01T) is a pediatric clinical trial that investigates the potential use of the drug trametinib (Mekinist®) as treatment for symptomatic or likely to become symptomatic NF1-related plexiform neurofibromas (PN) in children between 1 year and 17 year and 11 months of age. Trametinib is orally administered qd at 0.025 mg/kg up to a maximum of 2 mg from six years of age and 0.032mg/kilo up to 5 years of age, provided either as tablets or as oral solution. It is manufactured and distributed by Novartis under the trade name Mekinist®. The primary endpoint is remission of tumor volume ≥20%, evaluated using volumetric MRI at 18 and 30 months of treatment. The secondary endpoint is reversal of pain from NF1-related PN, evaluated monthly with agespecific pain scales; VAS scale (from 8 years) or Faces Pain Scale (from 3 to 8 years). As an exploratory measure, the potential effects of the treatment on the cognitive function will be assessed using well-established tests such as WISC-V (age range 6:0 - 16:11), NEPSY-II (age range 3:0-16:11), and CPT-3 (age range 8:0 - adult). Cognitive dysfunction is well described in patients with NF1, and the MAPK/ERK-pathway has been indicated to be involved in cognition.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date December 15, 2024
Est. primary completion date July 15, 2024
Accepts healthy volunteers No
Gender All
Age group 1 Year to 17 Years
Eligibility Inclusion Criteria - NF1-related PN with severe - or with high suspicion of becoming severe - manifestations - Informed consent provided - Age 1:0-17:11 Exclusion Criteria - NF1-related PN does not fulfill characteristics for acceptable volumetric MRI assessments as outlined under Criteria for volumetric assessment. - Lactating or pregnant females. Sexually active females, who do not (agree to) use safe contraception or adhere to regular controls during study. Sexually active males who do not (agree to) use a condom during coitus. - A history of other malignancies than classic NF1-related WHO grade 1 tumors (i.e. PN or optic pathway glioma). - A history of NF-1 related cerebral vascular anomalies (such as Moyamoya). - Active pharmaceutical therapy for optic pathway malignancy/ies. - Any medication for treatment of left ventricular systolic dysfunction. - Use of any investigational drug within 30 days of the first dose of this study treatment. - Impaired renal function (GFR under 45 ml/min/1,73m2 - It is only required to analyze eGFR if creatine is above institutional reference value for corresponding age group). - A known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drug or excipients that contraindicate their participation. - Active liver or biliary disease or moderate or severe liver impairment. If there are signs of liver disease (such as an increased prothrombin time or elevated transaminases),grading of the liver impairment has to be done in consultation with a hepatologist, since there is no universal definition. - A history of hepatic sinusoid obstructive syndrome (venoocclusive disease) within the last 3 months. - A history of heparin-induced thrombocytopenia. - A history of interstitial lung disease or pneumonitis. - A history of retinal vein occlusion (RVO). - A history of Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection. Subjects with a confirmed cleared HBV and HCV infection may be enrolled. - Presence of a condition that will interfere significantly with the absorption of drugs. - Evidence of cardiovascular risk, such as left ventricular ejection fraction (LVEF) below the lower limit of normal (LLN), a corrected QT-interval (Qtc) >480 milliseconds, clinically significant uncontrolled arrhythmia, congestive heart failure, or acute coronary syndrome or history thereof.

Study Design


Intervention

Drug:
Trametinib
treatment

Locations

Country Name City State
Sweden Skåne University Hospital Lund

Sponsors (2)

Lead Sponsor Collaborator
Region Skane Novartis

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Other Cognitive performance. Exploratory. WISC V. Change of full scale IQ or primary indexes of WISC V. Pooled data after 18 months versus before/at enrolment; with p-value <0.05. 0-18 months.
Other Cognitive performance. Exploratory. NEPSYII. Change of Learning and Memory functions and visuospatial functions, pooled data after 18 months versus before/at enrolment (selected test from NEPSYII,; with p-value <0.05. 0-18 months.
Other Cognitive performance. Exploratory. CPT3. Change in attention, pooled data after 18 months versus before/at enrolment (CPT-3); with p-value <0.05. 0-18 months.
Primary Remission of tumor volume =20% Final and primary analysis of primary outcome measure - of pooled data at 30 months (end of study) with volumetric mri of tumor volume versus volume at enrolment. 0 - 30 months.
Primary Remission of tumor volume =20% Interim analysis of pooled data at 18 months with volumetric mri of tumor volume versus volume at enrolment. This is an interim analysis of primary outcome and not primary analysis of primary outcome". 0 - 18 months
Secondary Reversal of NF1-related PN elicited - VAS scale pain Evaluated with monthly VAS pain scale from 8 years at enrolment. Monthly. 0-10 point scale. Descriptive. Analysis of pooled data after month 30. 0 - 30 months.
Secondary Reversal of NF1-related PN elicited pain - Faces Pain Scale Evaluated with monthly Faces Pain Scale from under 8 years at enrolment. Monthly. 0-10 scale. Descriptive. Analysis of pooled data after month 30. 0 - 30 months.
See also
  Status Clinical Trial Phase
Recruiting NCT06320626 - Pharmacokinetic-guided Dosing of Emicizumab Phase 4
Completed NCT04011852 - The Role of Chest Electrical Impedance Tomography in the Pediatric Ventilator Weaning
Completed NCT03497663 - VIA Family - Family Based Early Intervention Versus Treatment as Usual N/A
Recruiting NCT05016271 - Health Benefits of Air Purifiers in Primary School Students N/A
Completed NCT02551978 - Kids Obesity Prevention Program - Study (KOP) N/A
Completed NCT02240368 - Performance Evaluation of the Depth of Anesthesia Monitors in Pediatric Surgery
Completed NCT03946137 - Chest Therapy and Postural Education in Children With Cerebral Palsy N/A
Completed NCT01918020 - Impact Study of Minnesota SNAP-Ed Health and Nutrition Education Programs N/A
Completed NCT01267097 - The PAC Study: Parents as Agents of Change in Pediatric Weight Management N/A
Recruiting NCT04022460 - Using Personal Mobile Technology to Identify Obstructive Sleep Apnea in Children With Down Syndrome (UPLOAD)
Completed NCT05538039 - Reducing Anxiety of Children and Their Parents in the Pre-elective Surgery Process N/A
Completed NCT03156465 - Iowa Cochlear Implant Clinical Research Center Hybrid L24 and Standard Cochlear Implants in Profoundly Deaf Infants N/A
Not yet recruiting NCT05914324 - Outpatient Pediatric Pulse Oximeters in Africa N/A
Not yet recruiting NCT04827108 - Psychometric Properties of the Chinese Version of PeNAT
Recruiting NCT04888195 - Symptom Clusters in Hong Kong Chinese Children With Blood Cancer
Completed NCT05374902 - Efficacy of Animation, Buzzy, and Multiple Interventions on Pain in Children N/A
Not yet recruiting NCT04853303 - VR to Improve CINV, Sleep and Pain Among Children With Cancer in HK N/A
Completed NCT04665453 - Dexmedetomidine and Melatonin for Sleep Induction for EEG in Children N/A
Completed NCT04082247 - Healthy Children 2021 Study in Childcare Centers N/A
Completed NCT02858531 - Predictive Tracking of Patient Flow in the Emergency Services During the Virus Winter Epidemics

External Links